Load up as this is moving to phase 3 next week on 7 May 2021!!
$Palatin Tech(NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two presentations of the Company's melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021.nologies Inc(PTN.US)$
Phase 2 trial met the primary endpoints in the moderate to severe patient population but not in the overall population including mild patients. Data to be presented at ARVO May 6, 2021.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Kingzone6 : Keep it
Karheng Chong : Upupup
coolers : This stock is back alive !